Skip to main content
Fig. 7 | Translational Neurodegeneration

Fig. 7

From: Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1

Fig. 7

Alleviation of 6-OHDA-induced thermal hyperalgesia by DP. Within 5 min post-surgery, animals were treated with either 5 mg/kg DP or an equal volume of saline through daily intraperitoneal injection for 5 weeks. a Animals were tested for thermal hyperalgesia by assessing paw withdrawal frequency (%) using the acetone-evoked evaporation cooling test every week. A significant reduction in the frequency of paw withdrawal was observed after treatment with 5 mg/kg of DP from weeks 2 to 5 post-injury. b Animals were also tested for thermal hyperalgesia by assessing the paw withdrawal latency using the plantar test (Hargreaves Apparatus) at 52 °C every week. A significant increase in the paw withdrawal latency was observed after treatment with 5 mg/kg of DP from weeks 1 to 5 post-injury. *P < 0.05, **P < 0.01, compared to the 6-OHDA group. #P < 0.05, ##P < 0.01, compared to the sham group. ANOVA. Data are expressed as mean ± SD. n = 5 in each group

Back to article page